Eidos Therapeutics, a subsidiary of BridgeBio Pharma, is focused on developing AG10, a targeted therapeutic for transthyretin amyloidosis. The company's unique corporate model combines traditional drug development with early-stage science to quickly bring safe and effective treatments to market. Eidos was launched in 2016 with the support of Stanford's SPARK program and is led by experienced biotechnology executives. The company works closely with patients and physicians to achieve its mission of improving and prolonging the lives of those suffering from transthyretin amyloidosis.